AVLN Avalyn Pharma Inc. - common stock
NASDAQ · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 12, 2026
$28.13
· of 52w range
· above low
· to high
$24.1552w low
$40.1752w high
Market Cap (MRQ)
$1.25B
your badges
52W Range
$24–$40
Analyst Rating
BUY
Price Target
$62
P/E
·
ROE
·
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
AVLN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$28.13
Market Cap (MRQ)
$1.25B
Debt/Equity (MRQ)
0.0
52W Range
$24–$40
AVLN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | AVLN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | 3.1 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | AVLN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.0 | · | · | · | |
| Current Ratio (MRQ) | 33.1 | · | · | · | |
| Long-Term Debt / Equity (MRQ) | 0.0 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-18.6%
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $-0.98 | $-0.83 | -18.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $52M | |
| Short-term Investments | $86M | |
| Prepaid Expense | $5M | |
| Current Assets | $144M | |
| PP&E (Net) | $792.0K | |
| PP&E (Gross) | $846.0K | |
| Accum. Depreciation | $54.0K | |
| Other Non-current Assets | $3M | |
| Total Assets | $149M | |
| Accounts Payable | $4M | |
| Accrued Liabilities | $10M | |
| Current Liabilities | $14M | |
| Capital Leases | $1M | |
| Total Liabilities | $15M | |
| Common Stock | $24.0K | |
| Retained Earnings | $-265M | |
| AOCI | $134.0K | |
| Stockholders' Equity | $-239M | |
| Liabilities + Equity | $149M | |
| Shares Outstanding | 1,227,186 |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| R&D Expense | $25M | $23M | $18M | $15M | |
| SG&A Expense | $7M | $5M | $4M | $3M | |
| Operating Expenses | $31M | $28M | $22M | $19M | |
| Operating Income | $-31M | $-28M | $-22M | $-19M | |
| Interest Income | $3M | $1M | $2M | $1M | |
| Other Non-op | $-69.0K | $13.0K | $-41.0K | $-35.0K | |
| Income Tax | $0 | $0 | $0 | $0 | |
| Net Income | $-29M | $-27M | $-20M | $-18M | |
| EPS (Basic) | $-0.98 | $-21.83 | $-17.63 | $-63.24 | |
| EPS (Diluted) | $-0.98 | $-21.83 | $-17.63 | $-63.24 | |
| Shares (Basic) | 29,650,660 | 1,230,698 | 1,145,309 | 276,792 | |
| Shares (Diluted) | 29,650,660 | 1,230,698 | 1,145,309 | 276,792 | |
| EBITDA | $-31M | $-28M | · | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $264M | $92M | · | · | |
| Short-term Investments | $88M | $31M | · | · | |
| Prepaid Expense | $6M | $7M | · | · | |
| Current Assets | $358M | $130M | · | · | |
| PP&E (Net) | $1M | $1M | · | · | |
| PP&E (Gross) | $1M | $1M | · | · | |
| Accum. Depreciation | $216.0K | $117.0K | · | · | |
| Other Non-current Assets | $3M | $3M | · | · | |
| Total Assets | $425M | $136M | · | · | |
| Accounts Payable | $3M | $3M | · | · | |
| Accrued Liabilities | $7M | $8M | · | · | |
| Current Liabilities | $11M | $12M | · | · | |
| Capital Leases | $1M | $1M | · | · | |
| Total Liabilities | $27M | $28M | · | · | |
| Long-term Debt | $15M | $15M | · | · | |
| Total Debt | $15M | $15M | · | · | |
| Common Stock | $67.0K | $24.0K | · | · | |
| Retained Earnings | $-321M | $-292M | · | · | |
| AOCI | $-95.0K | $12.0K | · | · | |
| Stockholders' Equity | $398M | $-264M | · | · | |
| Liabilities + Equity | $425M | $136M | · | · | |
| Shares Outstanding | 44,333,094 | 1,232,442 | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Stock-based Comp | $3M | $1M | $1M | $543.0K | |
| Operating Cash Flow | $-26M | $-30M | $-21M | $-19M | |
| CapEx | $269.0K | $318.0K | $0 | $8.0K | |
| Investing Cash Flow | $-119M | $55M | $-37M | $24M | |
| Stock Issued | · | $50M | · | · | |
| Net Stock Activity | · | $50M | · | · | |
| Financing Cash Flow | $317M | $15M | $90M | $0 | |
| Free Cash Flow | · | $-30M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| ROA | -13.6% | -39.6% | · | · | |
| ROE | -14.5% | 20.3% | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Current Ratio | 33.1 | 11.0 | · | · | |
| Quick Ratio | 32.6 | 10.4 | · | · | |
| Debt / Equity | 0.0 | -0.1 | · | · | |
| LT Debt / Equity | 0.0 | -0.1 | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Book Value / Share | $8.99 | $-214.41 | · | · | |
| Cash Flow / Share | · | $-24.29 | · | · | |
| Cash / Share | $5.96 | $74.90 | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Market Cap | $1.46B | · | · | · | |
| Enterprise Value | $1.12B | · | · | · | |
| P/B | 3.7 | · | · | · | |
| P / Tangible Book | 3.7 | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| SR One Capital Management, LLC, SR One Capital Fund II Aggregator, LP, SR One Capital Partners II, LP, AMZL, LP, SR One Capital SMA Partners, LP, Simeon George | May 8, 2026 | 7.50% | Initial filing | Passive investment | SEC |
| SUVRETTA CAPITAL MANAGEMENT, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., Aaron Cowen | May 8, 2026 | 5.60% | Initial filing | Board campaign | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 14 insiders · 5 officers · 7 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Lyn Baranowski | Chief Executive Officer | April 29, 2026 A | · | 0 | 0 | $0 |
| Douglas R Carlson | Chief Financial Officer | April 30, 2026 A | · | 0 | 0 | $0 |
| Melissa Rhodes | Chief Operating Officer | April 29, 2026 A | · | 0 | 0 | $0 |
| Adam H. Golden | General Counsel | April 29, 2026 A | · | 0 | 0 | $0 |
| Howard Lazarus | Chief Medical Officer | April 29, 2026 A | · | 0 | 0 | $0 |
| Robert J. Meyer | Director | Sept. 15, 2026 A | · | 0 | 0 | $0 |
| Jill Carroll | Director | May 1, 2026 C | 2,186,562 | 1 | 0 | $5,000,004 |
| Erin Lavelle | Director | April 30, 2026 A | · | 0 | 0 | $0 |
| Kate Haviland | Director | April 29, 2026 A | · | 0 | 0 | $0 |
| Jon Congleton | Director | April 29, 2026 A | · | 0 | 0 | $0 |
| Heather D Turner | Director | April 29, 2026 A | · | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10% owner | May 1, 2026 C | 1,275,486 | 0 | 0 | $0 |
| FMR LLC | 10% owner | May 1, 2026 C | 2,284,535 | 0 | 0 | $0 |
| Novo Holdings A/S | · | May 1, 2026 C | 3,883,289 | 1 | 0 | $9,999,990 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 15 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IWO · iShares Trust | 0.03% | 110,766 SH | Sept. 11, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.03% | 2,408 SH | Oct. 2, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 98,545 SH | Aug. 19, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.02% | 12,713 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.02% | 435,913 SH | Sept. 11, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 192,602 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 4,638 SH | Aug. 19, 2026 | Daily |
| WSML · iShares Trust | 0.01% | 1,433 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 6,744 SH | Sept. 3, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 534,440 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 1,442 SH | Aug. 19, 2026 | Daily |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| IWN · iShares Trust | · | 48,795 SH | Sept. 11, 2026 | Daily |
| BNDX · VANGUARD CHARLOTTE FUNDS | · | · | July 15, 2026 | Daily |
| ISCB · iShares Trust | · | 852 SH | Sept. 11, 2026 | Daily |
AVLN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 10 analysts
BUY
Median target
$58.50
+108.0%
4 40.0%
Strong Buy
5 50.0%
Buy
1 10.0%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
4 analysts · 2026-09-28Mean target $62.25 +121.3%
← Below all targets
Current price $28.13
Low$52.00
Mean$62.25
High$80.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| AVLN | · | · | · | · | · | · |
| INVA | · | 6.1 | 14.7% | · | · | · |
| PAHC | · | 12.9 | 17.1% | 6.6% | 29.7% | 33.8% |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
| LBRX | $563M | -7.1 | · | · | -25.5% | · |
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| YARW | · | · | · | · | · | · |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 12, 2026